Noradrenaline Tartrato Hameln (Noradrenaline Tartrate)

Noradrenaline Tartrate is a vasopressor used in the management of acute cardiovascular emergencies.

• Hypotension: Restores arterial pressure in patients with severe low blood pressure unresponsive to fluid therapy.
• Shock: Improves perfusion by increasing systemic vascular resistance in various forms of distributive or cardiogenic shock.
• Cardiac arrest: Supports coronary and cerebral perfusion during resuscitation efforts.

• Noradrenaline Tartrate acts as an agonist at α1‑adrenergic receptors on vascular smooth muscle, causing vasoconstriction and raising systemic vascular resistance. It also stimulates β1‑adrenergic receptors in the heart, modestly increasing cardiac contractility and rate. The combined α‑mediated vasoconstriction and β‑mediated cardiac effects elevate arterial pressure, supporting organ perfusion in hypotensive states. These actions are rapid, dose‑dependent, and reversible upon discontinuation, allowing titration to target blood pressure.

Noradrenaline Tartrate may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache occurring during infusion.
• Tachycardia: increased heart rate due to β1‑adrenergic stimulation.
• Peripheral ischemia: reduced blood flow to extremities causing coldness or pain.
• Nausea: occasional nausea or vomiting.
• Hypertension: overshoot of blood pressure if dose is high.

Serious or Rare Side Effects

• Cardiac arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: reduced coronary blood flow leading to chest pain or infarction.
• Tissue necrosis: severe extravasation causing local tissue death.
• Severe hypertension: abrupt, uncontrolled rise in blood pressure.
• Pulmonary edema: fluid accumulation in lungs due to increased afterload.

When using Noradrenaline Tartrate, clinicians should observe specific precautions to minimize risks and ensure safe administration.

• Dose titration: Adjust infusion rate to achieve target blood pressure while avoiding excessive vasoconstriction.
• Cardiac monitoring: Continuously monitor heart rhythm and rate for arrhythmias.
• Peripheral perfusion: Inspect infusion site and distal extremities for signs of ischemia.
• Fluid status: Ensure adequate intravascular volume before initiating therapy.
• Drug compatibility: Administer through a dedicated line; avoid mixing with drugs that may precipitate.
• Store at ambient temperature: Keep the solution below 25 °C, protected from light and moisture in the original packaging.

Noradrenaline Tartrate can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• β‑blockers: May blunt the β1‑adrenergic cardiac effects, reducing desired increase in cardiac output.
• MAO inhibitors: Can potentiate hypertensive response, increasing risk of severe hypertension.
• Tricyclic antidepressants: May enhance vasoconstrictive effects leading to excessive blood pressure rise.

Moderate Interactions (Monitor Closely)

• Vasodilators (e.g., nitroglycerin): May counteract noradrenaline’s pressor effect, requiring dose adjustments.
• Calcium channel blockers: Can affect vascular tone and may increase risk of arrhythmias.
• Diuretics: May exacerbate hypovolemia, necessitating careful fluid management.